Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viaskin Milk for Milk-Induced Eosinophilic Esophagitis
NCT02579876Phase 2Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Viaskin Milk with Placebo (2 arms). Primary endpoint: Change in Maximum Esophageal Eosinophil Count From Baseline to End of Double-blind Treatment at 11 months. Started Oct 2015; status: completed.
02
Drugs
viaskin milk
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT02579876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579876.